Core Insights - Smith+Nephew has entered into a distribution agreement with SI-BONE to enhance its offerings in percutaneous pelvic fracture fixation procedures, particularly through the iFuse TORQ portfolio [1][3] - The partnership aims to leverage both companies' strengths to improve patient outcomes and expand access to innovative solutions in trauma procedures [3][4] Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with annual sales of $5.8 billion in 2024 [7] - The company operates in over 100 countries and is a constituent of the FTSE100 [7] Product Details - The iFuse TORQ portfolio includes iFuse TORQ TNT and iFuse TORQ implants, designed for pelvic fracture fixation and sacroiliac joint fusion, providing a competitive edge in the market [4][5] - iFuse TORQ TNT has received FDA Breakthrough Device Designation, indicating its potential for more effective treatment compared to traditional methods [5] Financial Implications - The iFuse TORQ TNT is eligible for a Medicare New Technology Add-on Payment, which could provide hospitals with up to $4,136 in additional reimbursement per procedure [5] Strategic Goals - The collaboration with SI-BONE reflects a commitment to innovation and clinical excellence, aiming to deepen surgeon engagement and drive sustainable growth in the trauma sector [3][4] - The partnership is expected to enhance Smith+Nephew's ability to serve surgeons and patients in high-need areas, thereby expanding its market presence [4]